Price
Target price
€6.22
€6.22
0.100%
0.006
0.100%
€7.45
18.09.24 / Tradegate
WKN: A0LC2W / Symbol: EBS / Name: Emergent Bio / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Emergent Biosolutions Inc. Stock
We see a rather positive sentiment for Emergent Biosolutions Inc. with 8 Buy predictions and 2 Sell predictions.
With a target price of 7 € there is a slightly positive potential of 12.47% for Emergent Biosolutions Inc. compared to the current price of 6.22 €.
Our community identified positive and negative aspects for Emergent Biosolutions Inc. stock for the coming years. 1 users see the criterium "Company culture" as a plus for the Emergent Biosolutions Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Emergent Biosolutions Inc. in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Emergent Biosolutions Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Emergent Biosolutions Inc. | 0.100% | -9.377% | -36.020% | 79.469% | 179.354% | -87.220% | -87.111% |
Ironwood Pharmaceuticals | 1.510% | 6.316% | 3.061% | -51.030% | -60.392% | -60.392% | -54.185% |
Arrowhead Pharmaceuticals Inc. | 4.280% | -1.604% | -9.199% | -28.986% | -33.576% | -66.102% | -29.548% |
Novocure Ltd | -2.190% | 1.503% | -2.218% | -12.320% | 11.173% | -85.811% | -77.946% |
Comments
Emergent BioSolutions Inc. (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Rodman & Renshaw. They now have a $16.00 price target on the stock.
Show more
Ratings data for EBS provided by MarketBeat
Emergent BioSolutions Inc. (NYSE: EBS) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $16.00 price target on the stock.
Show more
Ratings data for EBS provided by MarketBeat
Emergent BioSolutions Inc. (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $8.00 price target on the stock.
Show more
Ratings data for EBS provided by MarketBeat